Genetic variations in metabolic enzymes CYP3A4 and CYP2D6 and transport proteins like ABCB1 significantly impact the pharmacokinetics of ranolazine, influencing its levels, efficacy, and safety. These genetic differences can lead to altered metabolism and transport of the drug, affecting therapeutic outcomes and the risk of adverse effects like QT prolongation.